A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)

NCT ID: NCT04701658

Last Updated: 2021-11-16

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 109 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2021-02-01
• Study Completion Date: 2021-06-22

Brief Summary

The purpose of this study is to find out whether bamlanivimab is able to stop COVID-19 from getting worse. Participants with mild-to-moderate COVID-19 will receive bamlanivimab via an injection into a vein. These participants will be matched to similar COVID-19 patients who received other treatment at a local medical center. All participants will be followed to learn how their disease responds. Participation could last about 3 months and includes two required visits to the study site, with the remainder of assessments performed by phone or by medical record review.

Conditions

COVID-19

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Bamlanivimab

Participants received 700 milligram single intravenous infusion of Bamlanivimab.

Group Type: EXPERIMENTAL

Bamlanivimab

Intervention Type: DRUG

Administered intravenously.

Controls

Matched controls who received standard of care.

[The study was originally designed to include a matched control arm. However, due to low enrollment, it was amended to be a single arm study with Bamlanivimab arm only. No matched controls were utilized.]

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

Bamlanivimab

Administered intravenously.

Intervention Type: DRUG

Other Intervention Names

LY3819253; LY-CoV555

Eligibility Criteria

Inclusion Criteria

• Are currently not hospitalized.
• Have one or more mild or moderate COVID-19 symptoms.
• Must have first positive severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral infection determination and as soon as possible within 10 days of symptom onset
• Are males or non-breastfeeding females.
• Contraceptive use by males or females should be consistent with local regulations for those participating in clinical studies.
• Are at high risk for progressing to severe COVID-19 and/or hospitalization.

Exclusion Criteria

• Participants who:

• are hospitalized due to COVID-19, OR
• require oxygen therapy due to COVID-19, OR
• require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.
• Have peripheral capillary oxygen saturation (SpO2) less than or equal to (≤) 90 percent on room air or arterial partial pressure of oxygen/fraction of inspired oxygen (PaO2/FiO2) less than (<) 300, respiratory rate greater than or equal to (≥) 30 per minute, heart rate ≥125 per minute.
• Have body weight <40 kilograms.
• Require mechanical ventilation or anticipated impending need for mechanical ventilation.
• Have known allergies to any of the components used in the formulation of the interventions.
• Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention.
• Have any comorbidity requiring surgery within <7 days, or that is considered life-threatening within 29 days.
• Have any serious concomitant systemic disease, condition, or disorder that, in the opinion of the investigator, should preclude participation in this study.
• Have a history of a positive SARS-CoV-2 serology test.
• Have a history of a positive SARS-CoV-2 test prior to the one serving as eligibility for this study.
• Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30 days before dosing.
• Have received treatment with a SARS-CoV-2-specific monoclonal antibody, remdesivir, or other treatment for COVID-19.
• Have received convalescent COVID-19 plasma treatment.
• Have participated in a previous SARS-CoV-2 vaccine study.
• Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed.
• Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
• Are breast-feeding.

• Minimum Eligible Age: 12 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

AbCellera Biologics Inc.

INDUSTRY

Sponsor Role: collaborator

Eli Lilly and Company

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)

Role: STUDY_DIRECTOR

Eli Lilly and Company

Locations

Presbyterian Medical Center

Albuquerque, New Mexico, United States

Countries

United States

References

Kreuzberger N, Hirsch C, Chai KL, Tomlinson E, Khosravi Z, Popp M, Neidhardt M, Piechotta V, Salomon S, Valk SJ, Monsef I, Schmaderer C, Wood EM, So-Osman C, Roberts DJ, McQuilten Z, Estcourt LJ, Skoetz N. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19. Cochrane Database Syst Rev. 2021 Sep 2;9(9):CD013825. doi: 10.1002/14651858.CD013825.pub2.

Reference Type: DERIVED

PMID: 34473343 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Related Links

https://trials.lillytrialguide.com/en-US/trial/7zjYxdhUwux6y1A18CmrFJ

A Real World Study of Bamlanivimab in Participants With Mild-to-moderate Coronavirus Disease 2019 (COVID-19) (BLAZE-5)

Other Identifiers

J2X-MC-PYAJ

Identifier Type: OTHER

Identifier Source: secondary_id

18216

Identifier Type: -

Identifier Source: org_study_id